A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. , 2009
Reinders MK, Haagsma C, Jansen TLThA, van Roon EN, Delsing J, van de Laar MAFJ, Brouwers JRBJ. Ann Rheum Dis
Survey among Dutch rheumatologists on management of gout, 2009
Reinders MK, Brouwers JRBJ, Jansen TLThA. Ann Rheum Dis
Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol, 2009
Reinders MK, van Roon EN, Jansen TLThA, Delsing J, Griep EN, Hoekstra M, van de Laar MAFJ, Brouwers JRBJ. Ann Rheum Dis
Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients, 2007
Reinders MK, Van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Clin Rheumatol
Rasburicase treatment in severe tophaceous gout; a novel therapeutic option. , 2006
Moolenburgh JD, Reinders MK, Jansen TL. Clin Rheumatol
